Cargando…
Time-Prolonged Release of Tumor-Targeted Protein–MMAE Nanoconjugates from Implantable Hybrid Materials
The sustained release of small, tumor-targeted cytotoxic drugs is an unmet need in cancer therapies, which usually rely on punctual administration regimens of non-targeted drugs. Here, we have developed a novel concept of protein–drug nanoconjugates, which are packaged as slow-releasing chemically h...
Autores principales: | Serna, Naroa, Falgàs, Aïda, García-León, Annabel, Unzueta, Ugutz, Núñez, Yáiza, Sánchez-Chardi, Alejandro, Martínez-Torró, Carlos, Mangues, Ramón, Vazquez, Esther, Casanova, Isolda, Villaverde, Antonio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777625/ https://www.ncbi.nlm.nih.gov/pubmed/35057088 http://dx.doi.org/10.3390/pharmaceutics14010192 |
Ejemplares similares
-
Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4(+) Diffuse Large B-Cell Lymphoma Cells
por: Falgàs, Aïda, et al.
Publicado: (2021) -
An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination
por: Pallarès, Victor, et al.
Publicado: (2020) -
T22-PE24-H6 Nanotoxin Selectively Kills CXCR4-High Expressing AML Patient Cells In Vitro and Potently Blocks Dissemination In Vivo
por: Núñez, Yáiza, et al.
Publicado: (2023) -
Biparatopic Protein Nanoparticles for the Precision Therapy of CXCR4(+) Cancers
por: Cano-Garrido, Olivia, et al.
Publicado: (2021) -
Selective delivery of T22-PE24-H6 to CXCR4(+) diffuse large B-cell lymphoma cells leads to wide therapeutic index in a disseminated mouse model
por: Falgàs, Aïda, et al.
Publicado: (2020)